title: Immunotherapy Targeting WT1: Designing a Protocol for WT1 Peptide-Based Cancer Vaccine.
abstract: There is much current excitement about the potential of cancer immunotherapy. WT1 is high on the National Cancer Institute's list of priority antigens for immune therapy. In this chapter we describe a protocol for a clinical trial using a WT1 peptide-based cancer vaccine.
authors.affiliation: Department of Respiratory Medicine, Allergy and Rheumatic Disease, Graduate School of Medicine, Osaka University, 2-2, Yamada-Oka, Suita-City, Osaka, 565-0871, Japan. sumiyuki-n@imed3.med.osaka-u.ac.jp.
authors.forename: Sumiyuki
authors.initials: S
authors.lastname: Nishida
authors.affiliation: Department of Functional Diagnostic Science, Graduate School of Medicine, Osaka University, Osaka, Japan.
authors.forename: Haruo
authors.initials: H
authors.lastname: Sugiyama
mesh_terms: D019496:Cancer Vaccines / Q000008:administration & dosage* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D003713:Dendritic Cells / Q000276:immunology; D006801:Humans; D007167:Immunotherapy; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000276:immunology / Q000378:metabolism / Q000628:therapy*; D010455:Peptides / Q000008:administration & dosage* / Q000276:immunology / Q000627:therapeutic use; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D025721:WT1 Proteins / Q000378:metabolism*
chemical_list: D019496:Cancer Vaccines; D010455:Peptides; D025721:WT1 Proteins; C583751:WT1 protein, human
keywords: Cancer immunotherapy; Clinical trials; Cytotoxic T-lymphocytes; Dendritic cells; Peptide-based vaccines